Oscient to cut sales and marketing forces by 180

Share this article:
Waltham, MA-based Oscient Pharmaceuticals announced a restructuring that will result in 180 layoffs, including its 150-person sales force and approximately 30 other sales and marketing positions, the company said in a release. The layoffs with begin next month.

The cuts follow the company's decision – based on the conservation of financial resources – to discontinue sales force promotion on two products: Antara (fenofibrate), a cardiovascular drug, and Factive (gemifloxacin mesylate), an antibiotic. The products will continue to be available to physicians and patients.

The company reported a net loss of $11.5 million during the fourth quarter of 2008, up from a net loss of $14.7 million in Q4 2007, according to an annual report. Sales revenue for Antara was up during the same period, reaching $21.2 million during the fourth quarter, from $19.3 million during Q4 2007. Factive, however, decreased from $5.9 million during Q4 of 2007 to $5.1 million during Q4 2008, according to the report.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...